Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States.
The last earnings update was 51 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cidara Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cidara Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Cidara Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Cidara Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cidara Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cidara Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Cidara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cidara Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cidara Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 7.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Officer at Cidara Therapeutics, Inc. Dr. Stein serves as Principal Scientist of Verenium Corporation. He is Scientific Advisor of Spero Therapeutics, Inc. Dr. Stein served as Senior Vice President of Educational Strategy at MedCases, LLC. Dr. Stein served as a Principal Scientist of BASF Enzymes LLC. He also serves as a Faculty Research Associate at UC San Diego's Center for Marine Biotechnology and Biomedicine and in the Marine Biology Research Division of Scripps Institution of Oceanography. Dr. Stein was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein served as the President and Chief Executive Officer of Trius Therapeutics Inc. since February 2007. From 2005 to 2010, he was a Venture Partner at Sofinnova Ventures, Inc. He joined the Sofinnova Ventures, Inc. in May 2005 as a Kauffman Fellow at the Sofinnova Ventures till 2007 and was a part of the life science team. He works with Sofinnova's life science investment team to identify San Diego-based investment opportunities in the area of biopharmaceutical clinical development and advises the firm's life science portfolio companies on clinical and business matters. He has held senior scientific and management positions in the biopharmaceutical industry for the past 20 years. From 1999 to 2005, Dr. Stein was the Founder & Chief Scientific Officer of Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005 and also served as its Executive Vice President. He served as a Principal Scientist and head of the anti-infectives discovery team at Diversa Corporation. From 1995 to 1999, Dr. Stein was a scientist with the Diversa Corporation. From 1993 to 1995, he was a Principal Investigator at the Agouron Institute, where his laboratory developed techniques to clone and characterize microbial gene pathways. He serves on the Board of Rx3 Pharmaceuticals and Quorex. He has been a Director of IDEAYA Biosciences, Inc. since May 2016. He has been a Director of Paratek Pharmaceuticals, Inc. since October 30, 2014. He served as an Executive Director of Trius Therapeutics, Inc. since 2005. He served as a Director of Quorex Pharmaceuticals, Inc. He served as Director of Venture Development at University of California - San Diego. He was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein has also served as Director of Venture Development at UC San Diego from 2005 to 2006. He is considered an authority on the cloning and expression of microbial gene pathways and is a frequent invited lecturer on this topic at research and governmental institutions worldwide. he was a past member of the National Research Counsel’s Task Group for the Limits of Organic Life in Planetary Systems, a member of the President’s Panel on National Ocean Exploration Strategy and a past member of the National Science Foundation’s Engineering Center Site Review Team. Among the various honors he has received is the Thomas Alva Edison Patent Award. Dr. Stein holds a Ph.D. in Biochemistry and Marine Biology from the Scripps Institution of Oceanography of UC San Diego from the University of California as a NASA Fellow and conducted postdoctoral research in Bacterial Genetics as an Alexander Hollaender distinguished postdoctoral fellow at California Institute of Technology from 1991 to 1993. He received B.S. in Marine Biology and an M.S. in Biology from the California State University at Long Beach. He is Graduate Student Researcher Fellow at UCSD.
Jeff's compensation has increased whilst company is loss making.
Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Cidara Therapeutics management team is about average.
Chief Medical Officer
Founder and Chief Strategy Officer
Chief Financial Officer
COO & Chief Commercial Officer
Principal Accounting Officer
Chief Development Officer
Senior Vice President of Research
Chief Business Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Cidara Therapeutics board of directors is about average.
Board of Directors
Chairman of the Board
Who owns this company?
Recent Insider Trading
Cidara Therapeutics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.